This activity has expired. Credit is no longer available.
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Emerging Therapies for Multiple Myeloma

Patrick J. Kiel, PharmD, BCPS, BCOP
IU Simon Cancer Center

The overall survival of patients with multiple myeloma has increased within the past decade, thanks to newer agents such as immunomodulatory drugs and proteasome inhibitors. Receive updated data on key FDA approvals and practice updates for maximizing therapies while mitigating adverse events.


Download Slides

These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

in collaboration with

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.